Promising Interim Data in Phase 1/2 Hunter Syndrome Trial
source: shutterstock.com

Promising Interim Data in Phase 1/2 Hunter Syndrome Trial

Professionals from all corners of the world convene at SSIEM each year to discuss the latest groundbreaking discoveries. According to a report in BioSpace, one such breakthrough was presented by…

Continue Reading Promising Interim Data in Phase 1/2 Hunter Syndrome Trial
Rare Community Profiles: “The Boy in the Blue”: An MPS and Mental Health Awareness Project
source: shutterstock.com

Rare Community Profiles: “The Boy in the Blue”: An MPS and Mental Health Awareness Project

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: “The Boy in the Blue”: An MPS and Mental Health Awareness Project
Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders
source: pixabay.com

Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders

  According to an article in BioPortfolio, Magenta Therapeutics, a biotechnology company based in Cambridge, Mass., recently announced updates to its Phase II trial of MGTA-456 for the treatment of…

Continue Reading Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders
Interim Gene Therapy Trial Data for Two Different Forms of Sanfilippo Syndrome Holds Promise
source: pixabay.com

Interim Gene Therapy Trial Data for Two Different Forms of Sanfilippo Syndrome Holds Promise

According to a story from gurufocus.com, the biopharmaceutical company Abeona Therapeutics, Inc., recently announced the presentation of positive interim findings from two different phase 1/2 clinical trials. These trials were…

Continue Reading Interim Gene Therapy Trial Data for Two Different Forms of Sanfilippo Syndrome Holds Promise
An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
source: pixabay.com

An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit

  On February 3, 2020, twenty-seven newly installed flags of the European Union stood in the gleaming lobby of the new European Medicines Agency (EMA) headquarters in Amsterdam. The Charcot-Marie-Tooth…

Continue Reading An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
source: pixabay.com

Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference

According to a story from globenewswire.com, the biopharmaceutical company Inventiva is scheduled to present the findings from a recent phase IIa clinical trial at the upcoming 16th Annual WorldSymposium™ which is…

Continue Reading Inventiva Will Present Findings from Maroteaux-Lamy Syndrome Trial at Upcoming Conference
Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)
jarmoluk / Pixabay

Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)

Inventiva has recently completed Phase IIa of their clinical trial of odiparcil, a drug made for the treatment of mucopolysaccharidosis type VI (MPS VI). Iventiva is very excited about the…

Continue Reading Study: Odiparcil Shows Positive Results in Treatment of Mucopolysaccharidosis Type VI (MPS VI)

The Isaac Foundation has Turned to Television to Get Their Mucopolysaccharidosis Message Heard

The Isaac Foundation The Isaac Foundation was established by a man named Andrew McFadyen. He created the organization in 2007 in honor of  his son who is diagnosed with the rare…

Continue Reading The Isaac Foundation has Turned to Television to Get Their Mucopolysaccharidosis Message Heard
Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application
liaoyiye / Pixabay

Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application

According to a story from BioSpace, the biopharmaceutical company CANBridge Pharmaceuticals announced that it has recently submitted a New Drug Application with China's National Medicinal Products Administration (NMPA) for its…

Continue Reading Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application